P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress
نویسندگان
چکیده
منابع مشابه
Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
PURPOSE We performed this analysis to improve the understanding of the clinicopathological characteristics and clinical outcome of non-small cell lung cancer (NSCLC) patients harboring the primary epidermal growth factor receptor (EGFR) T790M mutation along with activating EGFR mutation. METHODS Resected tumors from 1903 NSCLC patients were analyzed for mutation in EGFR, as well as KRAS (Kirs...
متن کاملAfatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation
Afatinib is a second-generation of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and has shown a significant clinical benefit in non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. However, the potential therapeutic effects of afatinib combining with other modalities, including ionizing radiation (IR), are not well understood. In this study, we develo...
متن کاملCombination of icotinib and wogonin induces apoptosis and autophagy to overcome acquired resistance in lung cancer harbouring EGFR T790M mutation
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used as targeted chemotherapeutic drugs in the treatment of advanced non-small cell lung cancer (NSCLC). However, acquired resistance against TKIs caused by T790M mutation of EGFR has become a major clinical problem. In this study, we assessed whether the combination of wogonin, a natural monoflavonoid, and ico...
متن کاملThird-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.
The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, AS...
متن کاملNon-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer
BACKGROUND The increasing understanding of non-small cell lung cancer (NSCLC) biology over the last two decades has led to the identification of multiple molecular targets. This led to the development of multiple targeted therapies in the primary and secondary resistance setting and the epidermal growth factor receptor (EGFR) gene remains the most frequently observed molecular target in NSCLC. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2018
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2018.08.1599